Rare, predicted pathogenic variants in multiple sclerosis loci identified through novel multi-omics integration
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Illumina HiSeq 2000
ORGANISM(S): Homo Sapiens
SUBMITTER: Clinical institute of genomic medicine
PROVIDER: PRJEB110056 | EVA | 2026-03-17
REPOSITORIES: EVA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| MS_integ_anonymized_clean2.vcf.csi | Other | |||
| MS_integ_anonymized_clean2.vcf.gz | Vcf | |||
| MS_integ_anonymized_clean2.vcf.gz.csi | Vcf |
Items per page: 5 1 - 3 of 3 |
Similar Datasets
Project description:Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is much debated. This study explored the effect of purified IgG from SSc patients on the phenotype and function of healthy dermal fibroblast (FB) using an innovative multi-omics approach.
2022-06-29 | PXD025885 | Pride
Project description:Multi-tissue functional genomic study of systemic sclerosis
| PRJNA308610 | ENA
Project description:Pathway expression analysis in systemic sclerosis revealed key mediators driving pathology within each of the intrinsic gene expression subsets. Genome-wide expression profiling in systemic sclerosis (SSc) has identified four 'intrinsic' subsets of disease (fibroproliferative, inflammatory, limited, and normal-like), each of which appear to be driven by distinct signaling pathways. Here we examine experimentally derived gene expression signatures for thirteen agonists to better understand the molecular mechanisms underlying each intrinsic subsets. Pathway-specific gene signatures were compared against skin biopsy microarray data consisting of 329 microarray hybridizations from 287 unique biopsies representing 111 patients. Hierarchical clustering recapitulated the four SSc 'intrinsic' gene expression subsets, along with an intermediate subset exhibiting both inflammatory and fibroproliferative gene expression signatures. The fibroproliferative subset is most strongly associated with the PDGF gene signature, while the inflammatory subset demonstrated strong activation of NF-kappaB, characterized by early induction of TH2 signals, which transitions to a more TH17-like immune response over time. The limited subset was associated with IFNalpha signaling, combined with strong downregulation of PDGF signaling. The inflammatory-proliferative subset shows downregulation of NF-kappaB-associated pathways in conjunction with increased PDGF signaling, suggestive of a transitional state linking the inflammatory and fibroproliferative subsets. IL-13 signaling was strongly associated with early disease, while TGFbeta signaling was associated with more severe disease. Together these data suggest a multi-step, progressive model of disease pathogenesis driven by distinct pathways. Targeting these pathways based upon a patient's underlying disease subset should improve therapeutic outcomes. In vitro treatment of human dermal fibroblasts was performed to identify pathway-specific gene signatures. These gene signatures were then compared against systemic sclerosis skin biopsy microarrays to determine the overall contribution of each pathway to disease. This study includes re-analysis of 247 skin biopsy samples from GSE9285, GSE32413, and GSE45485. Links to these Samples are provided below. The re-processed normalized data for these Samples are included in the supplementary file 'GSE56308_247_Skin_Biopsy_Reanalysis_Samples.txt'.
2015-04-01 | E-GEOD-56308 | biostudies-arrayexpress
Project description:Upregulation of selected HERVW loci in Multiple Sclerosis
| PRJNA727565 | ENA
Project description:<p>Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with unclear etiology and no effective cure. Accumulating evidence implicates gut microbiota dysbiosis and circulatory metabolic al-terations in ALS pathogenesis, potentially driving disease progression and severity.</p><p>Methods: We enrolled 36 ALS patients and 32 healthy household relatives of these ALS patients as controls to minimize environmental confounders. Fecal (n=61) and serum (n=68) samples were analyzed using metagenomic sequencing for gut microbiota composition and untargeted metabolomics for fecal and serum metabolic profiles. Statistical and machine learning approaches, including principal coordinate analysis (PCoA), linear discriminant analysis effect size (LEfSe), and random forest modeling, identified differentially abundant taxa, metabolites, and biomarkers.</p><p>Results: ALS gut microbiota showed distinct beta diversity but unchanged alpha diversity. Pathogenic Proteobacteria (Enterobacteriaceae, Desulfovibrioaceae) increased, while beneficial Faecalibacterium and Clostridium decreased. A random forest model identified 20 microbial genera (AUC=0.89) and species (AUC=0.92) as ALS biomarkers. Microbial functions indicated hyperactive carbohydrate and amino acid metabolism and suppressed fatty acid metabolism. Fecal metabolomics revealed 722 altered metabolites (670 downregulated, e.g., lipids; 52 upregulated), disrupting phenylpropanoid biosynthesis and linoleic acid metabolism. Serum metabolomics showed lipid and choline metabolism perturbations. Reduced creatine and 2-hydroxybutyrate correlated with lower ALS Functional Rating Scale-Revised scores, while elevated diacylglycerols tracked disease severity. Symbiotic network analysis linked pathogenic Erysipelatoclostridium to reduced beneficial metabolites. Eubacterium was a central node, influencing metabolomes and BMI, with higher BMI correlating with Firmicutes enrichment (e.g., Ruminococcus).</p><p>Conclusion: ALS patients exhibit gut microbiota dysbiosis and circulatory metabolic disruptions, shaped by host factors like BMI and disease severity, correlating with disease progression. The microbiota-metabolite axis, elucidated through multi-omics and network analyses, offers targets for non-invasive biomarkers and therapies like microbiota modulation.</p>
2026-04-07 | MTBLS13295 | MetaboLights
Project description:The Australian Acute Care Genomics program provides ultra-rapid diagnostic testing to critically ill infants and children with suspected genetic conditions. Over two years, we performed whole genome sequencing (WGS) in 290 families, with average time to result of 2.9 days, and diagnostic yield of 47%. We performed additional bioinformatic analyses and transcriptome sequencing in all patients who remained undiagnosed. Long-read sequencing and functional assays, ranging from clinically accredited enzyme analysis to bespoke quantitative proteomics, were deployed in selected cases. This resulted in an additional 19 diagnoses, and an overall diagnostic yield of 54%. Diagnostic variants ranged from structural chromosomal abnormalities through to an intronic retrotransposon, disrupting splicing. Critical care management changed in 120 diagnosed patients (77%). Results informed precision treatments; surgical and transplant decisions; and palliation in 94 (60%). We propose that integration of multi-omic approaches into mainstream diagnostic practice is necessary to realise the full potential of genomic testing.
2023-10-24 | PXD042001 | Pride
Project description:It is fundamentally unknown how normal cellular processes or responses to extracellular stimuli may invoke polyadenylation and degradation of ncRNA substrates or if human disease processes exhibit defects in polyadenylation of ncRNA substrates as part of their pathogenesis. Our results demonstrate that mononuclear cells from subjects with relapsing-remitting multiple sclerosis (RRMS) exhibit pervasive increases in levels of polyadenylated ncRNAs including Y1 RNA, 18S and 28S rRNA, and U1, U2, and U4 snRNAs and these defects are unique to RRMS. Defects in expression of both Ro60 and La proteins in RRMS appear to contribute to increased polyadenylation of ncRNAs. Further, IFN-β1b, a common RRMS therapy, restores both Ro60 and La levels to normal as well as levels of polyadenylated Y1 RNA and U1 snRNA suggesting that aberrant polyadenylation of ncRNA substrates may have pathogenic consequences. We extracted RNA from peripheral whole blood in healthy control subjects and patients with established relapsing-remitting multiple sclerosis using PaxGene tubes.
2015-03-10 | E-GEOD-66573 | biostudies-arrayexpress
Project description: Not available
| S-EPMC5562556 | biostudies-literature
Project description:A method to stimulate T lymphocytes with a broad range of brain antigens would facilitate identification of the autoantigens for multiple sclerosis and enable definition of the pathogenic mechanisms important for multiple sclerosis. In previous work we found the obvious approach of culturing leukocytes with homogenized brain tissue does not work because the brain homogenate suppresses antigen-specific lymphocyte proliferation. We now report a method that substantially reduces the suppressive activity. We used this non-suppressive brain homogenate to stimulate leukocytes from multiple sclerosis patients and controls. We also stimulated with common viruses for comparison. We measured proliferation, selected the responding CD3+ cells with flow cytometry, and sequenced their transcriptomes for mRNA and T cell receptor sequences. The mRNA expression suggested the brain-responding cells from MS patients are potentially pathogenic. The T cell receptor repertoire of the brain-responding cells was clonal with minimal overlap with virus antigens.
2022-01-13 | GSE193260 | GEO